OUTCOMES AFTER CAR‐T CELL THERAPY (TISAGENLECLEUCEL OR AXICABTAGENE CILOLEUCEL) IN PATIENTS OLDER THAN 70 YEARS WITH DIFFUSE LARGE B CELL LYMPHOMA | Publicación